Advanced Search

    Technical Analysis for ARVN - Arvinas, Inc.

    Grade Last Price % Change Price Change
    F 27.68 -5.04% -1.47
    ARVN closed down 5.04 percent on Wednesday, March 22, 2023, on 78 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ARVN trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    20 DMA Resistance Bearish -5.04%
    Bearish Engulfing Bearish -5.04%
    180 Bearish Setup Bearish Swing Setup -5.04%
    Multiple of Ten Bearish Other -5.04%
    Outside Day Range Expansion -5.04%
    20 DMA Resistance Bearish -9.19%
    Multiple of Ten Bullish Other -9.19%
    Outside Day Range Expansion -9.19%
    Older End-of-Day Signals for ARVN ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    60 Minute Opening Range Breakdown about 9 hours ago
    Down 3% about 9 hours ago
    Up 1% about 14 hours ago
    Rose Above 10 DMA about 14 hours ago
    10 DMA Resistance about 14 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators Basic chart:

    Profile

    Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Disease Genetics Proprietary Technology Metabolism Chimera

    Is ARVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Feb 24 A Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)
    Feb 24 Arvinas Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
    Feb 23 Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
    Feb 23 Arvinas GAAP EPS of -$1.56 misses by $0.39, revenue of $38M beats by $2.68M
    Feb 23 Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
    Feb 6 Arvinas to Participate in Upcoming Investor Conferences
    Jan 28 12 Cash-Rich Small Cap Stocks To Invest In
    Jan 20 Bayer, Oerth Bio team up to develop sustainable crop protection products
    Jan 11 Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?
    Jan 9 Arvinas falls 17% after early-stage data for Pfizer-partnered tumor therapy
    See more ARVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 75.37
    52 Week Low 26.57
    Average Volume 474,580
    200-Day Moving Average 41.36
    50-Day Moving Average 32.09
    20-Day Moving Average 29.99
    10-Day Moving Average 28.98
    Average True Range 1.72
    RSI 36.71
    ADX 24.3
    +DI 13.61
    -DI 26.99
    Chandelier Exit (Long, 3 ATRs) 29.90
    Chandelier Exit (Short, 3 ATRs) 31.74
    Upper Bollinger Bands 32.70
    Lower Bollinger Band 27.27
    Percent B (%b) 0.08
    BandWidth 18.12
    MACD Line -1.09
    MACD Signal Line -1.10
    MACD Histogram 0.0058
    Fundamentals Value
    Market Cap 1.12 Billion
    Num Shares 40.5 Million
    EPS -7.16
    Price-to-Earnings (P/E) Ratio -3.87
    Price-to-Sales 39.19
    Price-to-Book 4.98
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 30.74
    Resistance 3 (R3) 31.06 30.36 30.23
    Resistance 2 (R2) 30.36 29.58 30.20 30.06
    Resistance 1 (R1) 29.02 29.10 28.67 28.70 29.89
    Pivot Point 28.32 28.32 28.15 28.16 28.32
    Support 1 (S1) 26.98 27.54 26.63 26.66 25.47
    Support 2 (S2) 26.28 27.06 26.12 25.30
    Support 3 (S3) 24.94 26.28 25.13
    Support 4 (S4) 24.62